ERBB2 and adenocarcinoma: In the phase III clinical trial KEYNOTE-811, pembrolizumab plus trastuzumab resulted in a significant reduction of tumor size and improved objective remission rates in patients with HER2-positive adenocarcinoma of the G/GEJ adenocarcinoma (ORR 74.4%) [108].